Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
$62.58
$49.26
▼
$70.98
$12.88B0.242.14 million shs2.30 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$80.34
$72.54
$33.61
▼
$118.84
$3.59B3.25646,345 shs434,331 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
$529.90
$393.61
▼
$615.00
$12.50B-0.98241,034 shs177,162 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.88%+4.26%+17.65%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%+0.43%+15.63%+30.59%+117.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+1.37%+6.09%+15.79%+24.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
$62.58
$49.26
▼
$70.98
$12.88B0.242.14 million shs2.30 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$80.34
$72.54
$33.61
▼
$118.84
$3.59B3.25646,345 shs434,331 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
$529.90
$393.61
▼
$615.00
$12.50B-0.98241,034 shs177,162 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.88%+4.26%+17.65%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%+0.43%+15.63%+30.59%+117.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+1.37%+6.09%+15.79%+24.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.74
Moderate Buy$89.1734.04% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.16% Downside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.30
Hold$67.78-15.64% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6429.30% Upside

Current Analyst Ratings Breakdown

Latest GRAL, EXEL, BMRN, and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $105.00
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$59.00 ➝ $60.00
8/26/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$88.00
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$60.00 ➝ $59.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B4.00$2.85 per share23.32$31.68 per share2.10
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.30$3.03 per share19.49$8.06 per share7.32
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M24.39N/AN/A$66.13 per share1.21
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M13.04N/AN/A$26.54 per share20.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37179.8112.210.482.14%5.32%3.69%10/26/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5615.861.7635.33%42.17%31.76%11/3/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A97.49N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)

Latest GRAL, EXEL, BMRN, and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36044.67 million43.85 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable

Recent News About These Companies

Public Employees Retirement System of Ohio Invests $2.74 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 6 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-invests-274-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-06/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
September 5 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-increases-stock-holdings-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-05/
Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-663-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-03/
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
September 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference-1036515145
Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355104/0/en/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference.html
Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-01/
The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-invests-655-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-31/
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993555
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-madrigal-pharmaceuticals-inc-nasdaq-mdgl-given-consensus-rating-of-moderate-buy-by-analysts-2026-08-31/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Wellington Management Group LLP
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-bought-by-wellington-management-group-llp-2026-08-30/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Algert Global LLC
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-sold-by-algert-global-llc-2026-08-30/
Hsbc Holdings PLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Canada Pension Plan Investment Board Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-takes-position-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bamco-inc-ny-makes-new-242-million-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-28/
Seven Fleet Capital Management LP Makes New $2.67 Billion Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-makes-new-267-billion-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-27/
Castleark Management LLC Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-castleark-management-llc-buys-new-stake-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-27/
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.1% - Here's What Happened
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-madrigal-pharmaceuticals-nasdaq-mdgl-trading-up-71-heres-what-happened-2026-08-26/
Paulson & CO. Inc. Invests $719.52 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-paulson-co-inc-invests-71952-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
Jupiter Topco LLC Buys Shares of 1,936,099 Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-buys-shares-of-1936099-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
J. Goldman & Co LP Buys New Shares in Madrigal Pharmaceuticals, Inc. $MDGL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-buys-new-shares-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-26/
9,980 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by EFG International AG
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-9980-shares-in-madrigal-pharmaceuticals-inc-mdgl-bought-by-efg-international-ag-2026-08-26/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.53 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.01 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$80.34 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$541.08 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas